STK33

Across TCGA pan-cancer cohorts, STK33 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STK33 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher STK33 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK33 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LSCC, UCEC, and PDAC are the cancer types where STK33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.589	0.813	.004	13	view →
UCEC	OS	Median	II,III,IV	0.590	1.000	.007	10	view →
PDAC	OS	Quartile	II,III,IV	0.959	0.725	.017	7	view →
CCRCC	OS	Median	All	1.000	0.911	.023	6	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.482	.026	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STK33–LSCC (DFS)

Open the LSCC breakdown →